Safety and efficacy of haploidentical hematopoietic stem-cell transplantation followed by post-transplant high-dose cyclophosphamide (RIC)

Safety and efficacy of haploidentical hematopoietic stem-cell transplantation followed by post-transplant high-dose cyclophosphamide (RIC) - Tsukuba-Haplo RIC

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015694

Enrollment

Registered

2015-01-01

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancy

Interventions

HLA-haploidentical hematopoietic stem-cell transplantation post-transplant high-dose cyclophosphamide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with hematological malignancy 2) Patients 16 to 65 years of age 3) Patients who do not have HLA antigen-matched (6/6) appropriate related donors 4) Patients who do not have HLA allele-matched (8/8) unrelated donors. 5) Patients with ECOG of 0, 1, or 2 6) Patients without severe dysfunction in the heart, the lung, the liver, and the kidney 7) Patients who gave written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with anti-HLA antibody 2) Patients with uncontrollable psychological complications 3) Patients with active double cancer 4) Patients with uncontrollable active infection 5) Pregnant women 6) Patients who are judged inappropriate by investigators

Design outcomes

Primary

Measure	Time frame
disease-free survival on day 100	—

Secondary

Measure	Time frame
overall survival, nonrelapse mortality, GVHD and relapse.	—

Countries

Japan

Contacts

Public ContactNaoki Kurita

University of Tsukuba Department of Hematology

n-kurita@umin.ac.jp029-853-3127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026